NCT05927571
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05927571
Title A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Genentech, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries ISR | AUS

Facility Status City State Zip Country Details
Royal Prince Alfred Hospital RECRUITING Camperdown New South Wales 2050 Australia Details
Calvary Mater Newcastle RECRUITING Waratah New South Wales 2298 Australia Details
Royal Adelaide Hospital;Haematology Clinical Trials Unit RECRUITING Adelaide South Australia 5000 Australia Details
The Alfred Hospital RECRUITING Prahan Victoria 3181 Australia Details
Rambam Health Care Campus RECRUITING Haifa 3109600 Israel Details
Hadassah University Hospital - Ein Kerem RECRUITING Jerusalem 9112001 Israel Details
Sheba Medical Center - PPDS RECRUITING Ramat Gan 5262000 Israel Details
Tel Aviv Sourasky Medical Center PPDS RECRUITING Tel Aviv 6423906 Israel Details
The Catholic University of Korea - Seoul St. Mary's Hospital (Kangnam St. Mary's Hospital) RECRUITING Seocho 06591 South Korea Details
Seoul National University Hospital RECRUITING Seoul 03080 South Korea Details
Samsung Medical Center - PPDS RECRUITING Seoul 06351 South Korea Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field